March 15, 2013 |
Experimental drug treatments promising to slow or reverse the progression of Alzheimer's disease will need to be assessed with a new and more subtle set of rules, a pair of FDA officials wrote this week. The resulting new guidelines, predict some researchers, should allow Alzheimer's drugs under development to travel a faster path to the U.S. market -- and to the more than 5 million Americans who need them. The new guidelines, issued to drug developers last month and outlined this week in the New England Journal of Medicine, reflect a growing shift among both physicians and researchers toward earlier detection and treatment of the memory-robbing disease.
CALIFORNIA | LOCAL
November 25, 1999
Molecular biologists have created a strain of mice that models one of the key features of Alzheimer's disease, the accumulation of "tangles" containing a protein called tau. The tangles, along with another deposit called plaque, are one of the key features of the disease, which affects as many as 4 million Americans. A team from the University of Pennsylvania reports in the November issue of Neuron that it added an extra copy of the tau gene to mice.
December 10, 2005 |
The diabetes drug Avandia can enhance memory in patients with mild Alzheimer's disease, but only in patients with a certain genetic profile, researchers from GlaxoSmithKline reported Wednesday at a UC San Diego meeting. The finding supports the hypothesis that impaired glucose metabolism may play a role in the onset of the disorder. The study, using about 500 patients, showed that the drug worked only in patients who did not have a gene variant known as ApoE4.
January 31, 2005 |
People who have high blood pressure, cholesterol, diabetes or who smoke in midlife have a much higher risk of developing Alzheimer's disease later on, U.S. researchers have found. And the more factors a person has, the higher the risk. People with all four risk factors have more than double the risk of Alzheimer's, reported a team at Kaiser Permanente's division of research in Oakland. "The message is that the risk factors that are bad for the heart are bad for the brain," said Dr.
September 5, 2002 |
A government-sponsored trial aimed at seeing if painkillers can reduce the risk of Alzheimer's disease is not only useless, but dangerous and should be stopped, Public Citizen said. The consumer group, which has lobbied against certain diet pills and other drugs, said the study is using the wrong drugs.
August 6, 1998 |
Seated in her recliner in the family room of the Long Beach duplex she shares with her identical twin, 87-year-old Ilene Eddy is reminiscing about their childhood back on the family farm in Iowa. At least she's trying to. Her twin, Irene Peterson, a few feet away in her own recliner with its matching floral chair cover, keeps interrupting. "Irene, be quiet, please!" Ilene says. "I'm trying to give information here."
CALIFORNIA | LOCAL
July 18, 1998 |
Every Sunday morning, I play softball with a bunch of guys at Cheviot Hills Park on the Westside. As teams go, we stink, but our wives and kids always turn out for the games. A couple of Sundays ago, as we warmed up, four strangers appeared on the dugout bleachers: an elderly man and woman and two thirtysomething fellows in jeans and baseball caps. A family enjoying the park, I assumed.
March 16, 1998 |
Former Sen. William Proxmire, the government gadfly who handed out Golden Fleece awards to spotlight what he considered bad uses of taxpayer money, has Alzheimer's disease, the Milwaukee Journal Sentinel reported. Proxmire, 82, a Democrat who retired in 1989 after 31 years in office, told the newspaper his condition "can be called Alzheimer's disease, although I'm not as bad as that sounds." He said he reads a lot but can't go on the lecture circuit or write his newspaper column.
May 21, 1998 |
Two Orange County drug developers became the latest firms swept up Wednesday in investors' euphoria over companies working on treatments for a variety of serious diseases. NeoTherapeutics Inc.'s stock more than doubled to $19.25 a share from $9.60, making it the biggest percentage gainer in U.S. markets, after the Irvine company reported encouraging results for a treatment for Alzheimer's disease. Earlier in the session, the stock hit an all-time high of $21.